{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:04:48Z","timestamp":1792800288499,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education - Kasturba Medical College, Mangalore","id":[{"id":"https:\/\/ror.org\/048vk1h54","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is an idiopathic disorder characterized by repeated relapses and remissions. Endoscopy, the gold standard for diagnosis and monitoring of these patients is time consuming, expensive, and invasive. Hence, faecal calprotectin (FCP) has been suggested as marker to determine the degree of intestinal inflammation and predict relapse in IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To use FCP as a predictor of clinical activity and endoscopic severity in IBD patients in a tertiary care hospital in Southern India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Study subjects underwent clinical examination, endoscopy, blood tests and stool FCP. For Endoscopic activity simple endoscopic score for Crohn\u2019s disease (SES-CD) and Ulcerative Colitis endoscopic index of severity (UCEIS) scores were used, and clinical activity was assessed by Crohn\u2019s disease activity index (CDAI) and simple clinical colitis index (SCCAI) for CD and UC respectively. At six months, blood, and stool FCP test were repeated which were compared with endoscopic and clinical activity indices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The number of males was higher in both CD (13\/8) and UC (19\/14). At first visit and follow up, CDAI and FCP were positively correlated (r-0.689, p- 0.016) (r- 0.425, p-value\u2009&lt;\u20090.05). In CD, the sensitivity and specificity of FCP in detecting active disease and remission were 93.8% and 80% respectively (AUC-0.869). At follow up, the sensitivity and specificity were 80% and 93.3% respectively (AUC-0.867). In patients with UC, SCCAI score and FCP levels positively correlated (r-0.231\/0.387, p-value 0.001\/0.001) at both the first and follow up visits. The sensitivity of FCP in detecting UC in active and remission states was 92.6% whereas the specificity was 83.3%. AUC was 0.88. At the time of follow up, the sensitivity of FCP in detecting UC in active and remission states was 89.9% whereas the specificity was 87.0% and AUC was 0.879.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirmed that FCP level shows strong association with clinical and endoscopic activity indices in patients of IBD. Therefore, FCP levels could be used as a surrogate marker for monitoring mucosal status as well as predicting endoscopic remission in IBD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04035-2","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:24:52Z","timestamp":1749029092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictive accuracy of fecal calprotectin in assessing clinical activity and disease severity in patients with Ulcerative Colitis and Crohn\u2019s disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Ankit V.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1089-0740","authenticated-orcid":false,"given":"Sandeep","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag J.","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. V.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0892-8551","authenticated-orcid":false,"given":"B.","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-3719","authenticated-orcid":false,"given":"Ramesh","family":"Holla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3792-0088","authenticated-orcid":false,"given":"Rishit","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"4035_CR1","doi-asserted-by":"crossref","unstructured":"S.Kulnigg and C.Gasche Systematic review: managing anaemia in Crohn\u2019s disease. Aliment Pharmacol Ther, 24, no. 11\u20132, pp. 1507\u20131523, 2006.","DOI":"10.1111\/j.1365-2036.2006.03146.x"},{"key":"4035_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12664-023-01430-z","volume":"43","author":"K Dharni","year":"2024","unstructured":"Dharni K, Singh A, Sharma S, et al. Trends of inflammatory bowel disease from the global burden of disease study (1990\u20132019). Indian J Gastroenterol. 2024;43:188\u201398.","journal-title":"Indian J Gastroenterol"},{"key":"4035_CR3","doi-asserted-by":"crossref","unstructured":"Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS). Gut. 2012;61:535\u201342.","DOI":"10.1136\/gutjnl-2011-300486"},{"key":"4035_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SESCD. Gastrointest Endosc. 2004;60:505\u201312.","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"4035_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","volume":"13","author":"A Sturm","year":"2018","unstructured":"Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR guideline for diagnostic assessment in Ibd part 2: Ibd scores and general principles and technical aspects. J Crohns Colitis. 2018;13(3):273\u201384.","journal-title":"J Crohns Colitis"},{"key":"4035_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426\u201331.","journal-title":"Gut"},{"key":"4035_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/ibd.20178","volume":"13","author":"MA Denis","year":"2007","unstructured":"Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn\u2019s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100\u20135.","journal-title":"Inflamm Bowel Dis"},{"key":"4035_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/mp.50.3.113","volume":"50","author":"B Johne","year":"1997","unstructured":"Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113\u201323.","journal-title":"Mol Pathol"},{"key":"4035_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1248\/bpb.26.753","volume":"26","author":"S Yui","year":"2003","unstructured":"Yui S, Nakatani Y, Mikami M, Calprotectin. (S100A8\/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis inducing activity. Biol Pharm Bull. 2003;26:753\u201360.","journal-title":"Biol Pharm Bull"},{"key":"4035_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000201441","volume":"58","author":"AG R\u00f8seth","year":"1997","unstructured":"R\u00f8seth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176\u201380.","journal-title":"Digestion"},{"key":"4035_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.gtc.2004.02.005","volume":"33","author":"JC Chang","year":"2004","unstructured":"Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin N Am. 2004;33:235\u201350.","journal-title":"Gastroenterol Clin N Am"},{"key":"4035_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1053\/j.gastro.2006.12.037","volume":"132","author":"C Su","year":"2007","unstructured":"Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516\u201326.","journal-title":"Gastroenterology"},{"key":"4035_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.crohns.2011.07.003","volume":"5","author":"M Daperno","year":"2011","unstructured":"Daperno M, Castiglione F, Ridder L, et al. Results of the 2nd part scientific workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484\u201398.","journal-title":"J Crohns Colitis"},{"key":"4035_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/01.mpg.0000187818.76954.9a","volume":"42","author":"RB Canani","year":"2006","unstructured":"Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9\u201315.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4035_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/gut.2004.056358","volume":"54","author":"PD Higgins","year":"2005","unstructured":"Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782\u20138.","journal-title":"Gut"},{"issue":"2","key":"4035_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/jgh3.12686","volume":"6","author":"A Kale","year":"2022","unstructured":"Kale A, Shinde L, Sundaram S, Patra BR, Rao PK, Irtaza M, Shukla A. COVID-19 pandemic and inflammatory bowel disease from patients\u2019 perspective: A survey from COVID epicenter in India. JGH Open. 2022;6(2):126\u201331.","journal-title":"JGH Open"},{"issue":"3","key":"4035_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.15403\/jgld.2014.1121.273.pti","volume":"27","author":"T Rokkas","year":"2018","unstructured":"Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018;27(3):299\u2013306.","journal-title":"J Gastrointestin Liver Dis"},{"key":"4035_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/00054725-200606000-00013","volume":"12","author":"MR Konikoff","year":"2006","unstructured":"Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524\u201334.","journal-title":"Inflamm Bowel Dis"},{"issue":"48","key":"4035_CR19","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.3748\/wjg.v21.i48.13566","volume":"21","author":"WC Lin","year":"2015","unstructured":"Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC. Taiwan society of inflammatory bowel disease multicenter study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol. 2015;21(48):13566\u201373.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4035_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3904\/kjim.2016.324","volume":"34","author":"YW Lee","year":"2019","unstructured":"Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med. 2019;34(1):72\u201380.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"4035_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.31080\/ASPE.2022.05.0488","volume":"5","author":"MP Narayanan","year":"2022","unstructured":"Narayanan MP, Vasudevan DM. Faecal calprotectin in inflammatory bowel diseases. Acta Sci Paediatrics. 2022;5(1):21\u20134.","journal-title":"Acta Sci Paediatrics"},{"issue":"2","key":"4035_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5217\/ir.2021.00064","volume":"20","author":"N Kamat","year":"2022","unstructured":"Kamat N, Vuyyuru SK, Kedia S, Sahu P, Kante B, Kumar P, Ranjan MK, Singh MK, Kumar S, Sachdev V, Makharia G, Ahuja V. Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis. Intest Res. 2022;20(2):269\u201373.","journal-title":"Intest Res"},{"key":"4035_CR23","first-page":"A116","volume":"70","author":"M Samaan","year":"2021","unstructured":"Samaan M, Cunningham G, Tamilarasan G, et al. P143\u2005Validation of the two-item UC PRO2 against SCCAI, biochemical disease activity and quality of. LifeGut. 2021;70:A116\u20137.","journal-title":"LifeGut"},{"key":"4035_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","volume":"19","author":"AM Schoepfer","year":"2013","unstructured":"Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332\u201341.","journal-title":"Inflamm Bowel Dis"},{"key":"4035_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/1756-0500-2-221","volume":"2","author":"A Vieira","year":"2009","unstructured":"Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes. 2009;2:221.","journal-title":"BMC Res Notes"},{"issue":"5","key":"4035_CR26","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)","year":"2021","unstructured":"Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD). Determining therapeutic goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04035-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:24:53Z","timestamp":1749029093000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04035-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4035"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04035-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Received the approval from the Institutional Ethics Committee of Kasturba Medical College, Mangalore IEC KMC MLR 11\/2021\/332. Research adhered to standard norms of data collection and interpretation as laid down by the ethics committee which are in accordance to Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the participants were explained in detail about the study in the language they duly comprehend, following which the voluntary consent for participation was taken from all the participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"429"}}